Speaker: Jenna Frame, Ph.D.  Manager, Scientific Communications & Marketing, Biocytogen Boston

• Reviewed the mechanisms driving NK cell activity in the context of immuno-oncology, and the types of NK-targeted immunotherapies currently under investigation
• Introduced experimental models used to evaluate these immunotherapies, including syngeneic models and xenograft models